On Jan. 20, 2022, scientists from the National Institute of Allergy and Infectious Diseases (NIAID) announced that they had developed an array of monoclonal antibodies from recovered COVID-19 patients, and two of the therapeutic treatments in a recent study neutralized a variety of disease-causing virus variants.

The study, not peer reviewed but posted on medRxiv, showed that the monoclonal antibodies have ﾓultrapotent neutralizing activityﾔ against SARS-CoV-2, the virus that causes COVID-19.